Vaginal Atrophy following Long-Term Depot Medroxyprogesterone Acetate Use: A Case Report
Depot medroxyprogesterone acetate (DMPA) is a commonly used form of contraception, with noncontraceptive benefits for the user. The mode of action is through the suppression of ovulation. It leads to hypoestrogenism which causes dryness of the vagina and dyspareunia. We present in this paper a patie...
Saved in:
Main Authors: | Christie Walker, Shawky Z. A. Badawy |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2013-01-01
|
Series: | Case Reports in Obstetrics and Gynecology |
Online Access: | http://dx.doi.org/10.1155/2013/835316 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Protective Effect of Vitamins C and E on Depot-Medroxyprogesterone Acetate-Induced Ovarian Oxidative Stress In Vivo
by: Atik Ismiyati, et al.
Published: (2016-01-01) -
Spatial transcriptomics unveils estrogen-modulated immune responses and structural alterations in the ectocervical mucosa of depot medroxyprogesterone acetate users
by: Vilde Kaldhusdal, et al.
Published: (2025-01-01) -
Medroxyprogesterone Acetate Plus Metformin to Prevent Persistent Endometrial Hyperplasia
by: Vakkas Korkmaz, et al.
Published: (2013-08-01) -
Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data
by: Luyang Su, et al.
Published: (2024-12-01) -
Assessment of Human-originated Medroxyprogesterone Acetate (MPA) as Effective Contraceptive in Domesticated Queens (Felis catus) in Iraq
by: Mushtaq A Alabodi, et al.
Published: (2024-12-01)